19.43

6.25% +1.19

MediWound Ltd (MDWD)

Overview News Price History Option Chain Discussions Forecast Stock Split

MediWound Ltd stock is currently priced at $19.43, with a 24-hour trading volume of 50,170. It has seen a +6.25% increased in the last 24 hours and a +36.00% rose in the past month. The chart indicates a potential bullish trend, as the stock is above the $18.13 pivot point. If it approaches the $19.47 resistance level, significant changes may occur.

Previous Close:

$18.24

Open:

$18.2

24h Volume:

50,170

Market Cap:

$181.67M

Revenue:

$18.69M

Net Income/Loss:

$-6.72M

P/E Ratio:

-7.9959

EPS:

-2.43

Net Cash Flow:

$-16.93M

1W Performance:

+22.97%

1M Performance:

+36.00%

6M Performance:

+149.42%

1Y Performance:

+68.38%

1D Range:

$18.20

$19.43

52W Range:

$7.10

$19.38

MediWound Ltd Stock (MDWD) Company Profile

Name

MediWound Ltd

Sector

Healthcare (1203)

Industry

Biotechnology (688)

Phone

972 7 797 14100

Address

42 Hayarkon Street, Yavne

Employee

Twitter

Next Earnings Date

2024-05-28

Latest SEC Filings

MDWD's Discussions on Twitter

MediWound Ltd Stock (MDWD) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-22-22	Initiated	Maxim Group	Buy
Jul-18-22	Resumed	Oppenheimer	Outperform
Sep-23-20	Initiated	BTIG Research	Buy
Nov-28-16	Initiated	Aegis Capital	Buy
Aug-17-16	Initiated	Wells Fargo	Outperform
Apr-16-14	Initiated	Oppenheimer	Outperform

View All

MediWound Ltd Stock (MDWD) Latest News

Strength Seen in MediWound (MDWD): Can Its 14.3% Jump Turn into More Strength?

Zacks Investment Research

Wall Street Analysts See a 76.89% Upside in MediWound (MDWD): Can the Stock Really Move This High?

Zacks Investment Research

MediWound Ltd Stock (MDWD) Financials Data

MediWound Ltd (MDWD) Revenue 2024

MDWD reported a revenue (TTM) of $18.69 million for the quarter ending December 31, 2023, a -29.48% decline year-over-year.

MediWound Ltd (MDWD) Net Income 2024

MDWD net income (TTM) was -$6.72 million for the quarter ending December 31, 2023, a +65.73% increase year-over-year.

MediWound Ltd (MDWD) Cash Flow 2024

MDWD recorded a free cash flow (TTM) of -$16.93 million for the quarter ending December 31, 2023, a -36.09% decrease year-over-year.

MediWound Ltd (MDWD) Earnings per Share 2024

MDWD earnings per share (TTM) was -$0.77 for the quarter ending December 31, 2023, a +80.00% growth year-over-year.

MediWound Ltd., an integrated biopharmaceutical company, focuses on developing, manufacturing, and commercializing novel therapeutics products to address unmet needs. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns in the European Union, Israel, and Argentina. The company also develops EscharEx, which is in Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.